MARKET

NEO

NEO

Neogenomics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

50.64
-0.22
-0.43%
Opening 14:41 02/26 EST
OPEN
51.32
PREV CLOSE
50.86
HIGH
51.72
LOW
49.32
VOLUME
446.51K
TURNOVER
--
52 WEEK HIGH
61.57
52 WEEK LOW
20.47
MARKET CAP
5.86B
P/E (TTM)
-1548.6239
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
10-K: NEOGENOMICS INC
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Introduction The following...
Edgar Online - (EDG = 10Q, 10K) · 21h ago
DJ NeoGenomics Is Maintained at Overweight by Morgan Stanley
Dow Jones · 1d ago
DJ NeoGenomics Price Target Raised to $64.00/Share From $46.00 by Morgan Stanley
Dow Jones · 1d ago
Morgan Stanley Maintains Overweight on NeoGenomics, Raises Price Target to $64
Morgan Stanley analyst Tejas Savant maintains NeoGenomics (NASDAQ:NEO) with a Overweight and raises the price target from $46 to $64.
Benzinga · 1d ago
--Analyst Actions: Morgan Stanley Adjusts Price Target on NeoGenomics to $64 From $46, Maintains Overweight Rating
MT Newswires · 1d ago
DJ NeoGenomics Price Target Announced at $65.00/Share by Needham
Dow Jones · 1d ago
DJ NeoGenomics Coverage Assumed by Needham at Buy
Dow Jones · 1d ago
DJ NeoGenomics Cut to Market Perform From Outperform by Raymond James
Dow Jones · 1d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NEO. Analyze the recent business situations of Neogenomics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 12 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NEO stock price target is 64.60 with a high estimate of 70.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 455
Institutional Holdings: 115.14M
% Owned: 99.51%
Shares Outstanding: 115.70M
TypeInstitutionsShares
Increased
97
5.83M
New
83
666.44K
Decreased
113
4.56M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Healthcare Facilities & Services
-0.59%
Healthcare Providers & Services
+0.30%
Key Executives
Chairman/Chief Executive Officer/Director
Douglas VanOort
President
George Cardoza
Chief Financial Officer
Kathryn McKenzie
Corporate Executive
Robert Shovlin
Chief Accounting Officer/Controller
Cynthia Dieter
Chief Information Officer
Steven Ross
Chief Compliance Officer
Stephanie Bywater
Vice President
Jennifer Balliet
General Counsel/Secretary
Denise Pedulla
Director of Investor Relations/IR Contact Officer
William Bonello
Other
Douglas Brown
Other
Lawrence Weiss
Lead Director/Independent Director
Lynn Tetrault
Director
Steven Jones
Director
Rachel Stahler
Independent Director
Bruce Crowther
Independent Director
Alison Hannah
Independent Director
Raymond Hipp
Independent Director
Kevin Johnson
Independent Director
Stephen Kanovsky
Independent Director
Michael Kelly
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About NEO
NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee. It offers testing services, which include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Immunohistochemistry (IHC), Molecular testing and Pathology consultation. Its Pharma Services and Clinical Trials group provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. It helps its customers develop a biomarker hypothesis by recommending an optimal platform for molecular screening and backing its discovery tools with the informatics to capture meaningful data.

Webull offers kinds of NeoGenomics, Inc. stock information, including NASDAQ:NEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NEO stock methods without spending real money on the virtual paper trading platform.